Comparative Pharmacology
Head-to-head clinical analysis: CHLOROPTIC versus TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROPTIC versus TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE.
CHLOROPTIC vs TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloroptic (chloramphenicol) inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby inhibiting thymidine synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides in Gram-negative bacteria.
1 drop (0.5% solution) into the affected eye(s) every 4-6 hours.
One drop in each affected eye every 2 to 4 hours for 7 to 10 days.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function, necessitating frequent dosing (every 4-6 hours) to maintain therapeutic levels.
Trimethoprim: 8-10 hours (normal renal function); Polymyxin B: 6 hours (prolonged in renal impairment).
Primarily renal elimination (70-80% as unchanged drug). Minor biliary/fecal excretion (<10%).
Trimethoprim: renal (80-90% unchanged, 10-20% metabolites); Polymyxin B: renal (60% unchanged, 40% nonrenal).
Category C
Category D/X
Antibiotic
Antibiotic